Get the Stockscreener App
6.915
0.15%
-0.045
Verastem Inc stock is traded at $6.915, with a volume of 102.30K.
It is down -0.15% in the last 24 hours and down -33.78% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$6.87
Open:
$6.83
24h Volume:
102.30K
Relative Volume:
0.05
Market Cap:
$520.84M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-1.6825
EPS:
-4.11
Net Cash Flow:
$-86.46M
1W Performance:
-9.02%
1M Performance:
-33.78%
6M Performance:
+42.92%
1Y Performance:
+2.08%
1-Day Range:
$6.77
$6.9675
1-Week Range:
$6.68
$7.77
52-Week Range:
$4.01
$11.24
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
6.915 | 517.45M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.70 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.49 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
393.09 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.04 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.03 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-10-25 | Initiated | Jefferies | Buy |
| Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
What's Going On With Verastem Stock Friday?Verastem (NASDAQ:VSTM) - Benzinga
Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC - MSN
Verastem Ends Lung Cancer Trial, Reallocates Resources - Sahm
Verastem Oncology stock drops after hours after discontinuing a clinical trial in lung cancer - MSN
Verastem stock steady as Mizuho reiterates Outperform rating By Investing.com - Investing.com Canada
Verastem Shifts Focus to KRAS G12D and Pancreatic Programs - TipRanks
Verastem to discontinue Avmapki/Fakzynja combo in KRAS G12C-mutated NSCLC - The Pharma Letter
Verastem (VSTM) Halts Development of Avutometinib/Defactinib Com - GuruFocus
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC (VSTM) - Seeking Alpha
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch - ts2.tech
Verastem (NASDAQ:VSTM) Shares Cross Above 200 Day Moving AverageShould You Sell? - MarketBeat
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Verastem Oncology (VSTM) Shifts Focus to Promising KRAS G12D Inh - GuruFocus
Calkins, Verastem CFO, sells $628 in shares By Investing.com - Investing.com South Africa
Verastem Oncology provides update on Ramp 203 phase 1/2 clinical trial - marketscreener.com
Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer - Stocktwits
Verastem to Discontinue RAMP 203 Clinical Trial in Lung Cancer After Interim Data Read - marketscreener.com
Verastem stock falls after discontinuing KRAS G12C lung cancer trial By Investing.com - Investing.com Nigeria
Verastem (VSTM) Shifts Focus to Promising KRAS G12D Inhibitor in Cancer Treatment - GuruFocus
Verastem stock falls after discontinuing KRAS G12C lung cancer trial - Investing.com
Verastem discontinues KRAS G12C lung cancer trial to focus on G12D - Investing.com Canada
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Business Wire
Calkins, Verastem CFO, sells $628 in shares - Investing.com India
Behavioral Patterns of VSTM and Institutional Flows - Stock Traders Daily
Verastem, Inc.'s (NASDAQ:VSTM) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors - 富途牛牛
Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump - simplywall.st
Is Verastem Inc a good long term investmentAI-Driven Market Analysis & Double Digit Wealth Tips - earlytimes.in
Will Verastem Inc. stock outperform Nasdaq indexJuly 2025 Final Week & Consistent Profit Trade Alerts - Улправда
Verastem (STU:2VS) EV-to-OCF : -3.85 (As of Dec. 20, 2025) - GuruFocus
Can Verastem Inc. stock surprise with earnings upsideQuarterly Portfolio Review & Low Risk Entry Point Guides - Улправда
Squarepoint Ops LLC Boosts Stake in Verastem, Inc. $VSTM - MarketBeat
Can Verastem Inc. stock sustain revenue growthJuly 2025 News Drivers & AI Powered Buy/Sell Recommendations - Улправда
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Mizuho maintains Verastem stock outperform with $9 target - MSN
Is Verastem Inc. stock vulnerable to regulatory risksQuarterly Growth Report & Low Risk High Win Rate Stock Picks - Улправда
Verastem streamlines leadership team amid strategic transition - MSN
Verastem, Inc. Announces Departure of Chief Operating Officer - TradingView — Track All Markets
Why Verastem Inc. stock could benefit from AI revolutionGDP Growth & Fast Exit Strategy with Risk Control - bolumsonucanavari.com
How Verastem Inc. (2VSA) stock moves in volatile trading sessionsJuly 2025 Patterns & Real-Time Buy Signal Alerts - Улправда
Will Verastem Inc. stock benefit from green energy trendsQuarterly Growth Report & Expert Approved Momentum Trade Ideas - Улправда
Insider Sell Alert: Brian Stuglik Sells Shares of Verastem Inc (VSTM) - GuruFocus
Dir Stuglik Surrenders 592 Of Verastem Inc [VSTM] - TradingView — Track All Markets
[Form 4] Verastem, Inc. Insider Trading Activity - Stock Titan
Verastem (VSTM) CEO sells 393 shares tied to RSU vesting - Stock Titan
Verastem (VSTM) director reports 283-share sale for RSU tax withholding - Stock Titan
RSI Check: Is Verastem Inc. stock a defensive play in 2025Earnings Overview Report & AI Enhanced Execution Alerts - ulpravda.ru
Verastem Oncology announces management changes - MSN
Guggenheim Keeps Their Buy Rating on Verastem (VSTM) - The Globe and Mail
Risk Report: Can Verastem Inc stock continue upward trend2025 Year in Review & Weekly Watchlist of Top Performers - moha.gov.vn
Verastem announces strategic leadership changes for growth By Investing.com - Investing.com Australia
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):